X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

WHO Revises Treatment Recommendations For Drug-Resistant TB

Content Team by Content Team
20th December 2022
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The World Health Organization (WHO) has released its revised consolidated recommendations for treating drug-resistant tuberculosis (DR-TB), which include significant advancements in the treatment options available to individuals with MDR or RR-TB: multidrug-resistant or rifampicin-resistant tuberculosis) and a regimen that provides better patient outcomes.

For patients with MDR/RR-TB or MDR/RR-TB with added fluoroquinolone resistance, a unique all-oral six-month regimen composed of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is recommended in the 2022 updates (pre-XDR-TB). For those with MDR/RR-TB, the new regimen dramatically improves quality of life by providing better results and significantly cutting down on treatment time.

Who can use the 2022 update from the World Health Organization?

The publication contains all current recommendations for treating DR-TB, and it is reinforced with an operational manual created to make it easier for Member States, technical partners, and those in charge of managing patients with DR-TB to put the WHO recommendations into practice. The new suggestions offer helpful advice on how to implement the suggested therapeutic choices at a national and international level to facilitate a good impact.

The material is intended for national TB programmes or their equivalent in Ministries of Health, policymakers, and technical organisations engaged in TB and infectious disease research in the public and private sectors as well as in the community.

The new BPaLM/BPaL treatment combination will be less expensive and more widely available as a result of new projects by the public and private sectors to lower the price of protomanid and possibly other component drugs.

Implementing the new tuberculosis drug-resistant treatment protocol

The WHO has stated that it intends to establish a regular online discussion platform with the participation of high MDR/RR-TB burden nations, civil society, technical partners, and the donor community to assist the introduction of the new DR-TB treatment regimen.

They now have a better and quicker all-oral therapy alternative for drug-resistant tuberculosis thanks to the newly accessible data. As Director of WHO’s Global TB Programme, Dr. Tereza Kasaeva, noted that it is a historic move that will be of immense help to people suffering with drug-resistant TB, relieving the strain on health systems, and saving lives. They now urge partners and national TB programmes to take immediate action to switch over to the new drug-resistant TB treatment protocol.

Previous Post

By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

Next Post

Hemophilia Gene Therapy Now Backed By European Regulators

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Hemophilia Gene Therapy Now Backed By European Regulators

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In